|
Jun 30
|
TME Pharma Announces New Treasury Investment Policy
|
|
Jun 27
|
TME Pharma Provides Results of Final Exercise of Warrants Z
|
|
Jun 25
|
TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders
|
|
Apr 10
|
TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities
|
|
Feb 17
|
TME Pharma CEO Message
|
|
Jul 9
|
TME Pharma N.V.: CEO Message H1 2024
|
|
Feb 23
|
TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024
|
|
Jan 9
|
TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer
|
|
Dec 20
|
TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial
|
|
Nov 28
|
TME Pharma Announces the Initiation of the Listing of Preferential Subscription Rights for Fully Guaranteed €2.7 Million Capital Increase
|
|
Oct 20
|
TME Pharma Announces Further Improvement in Overall Survival at 18 Months to 67% for NOX-A12 Combination Regimen in Brain Cancer
|
|
Jul 20
|
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
|